SCHEMBL1552771

SCHEMBL1552771

O=C1NC(=O)C2(c3ccccc3)CC12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.69
CACNA1F O60840 2/20 0.44
SCN1A P35498 2/20 0.44
SCN4A P35499 2/20 0.44
CACNA1D Q01668 2/20 0.44
KCNH2 Q12809 2/20 0.44
CACNA1S Q13698 2/20 0.44
CACNA1C Q13936 2/20 0.44
SCN5A Q14524 2/20 0.44
SCN2A Q99250 2/20 0.44
SCN3A Q9NY46 2/20 0.44
AR P10275 1/20 0.44
PDE4A P27815 1/20 0.44
SCN7A Q01118 1/20 0.44
SCN9A Q15858 1/20 0.44
SCN11A Q9UI33 1/20 0.44
SCN8A Q9UQD0 1/20 0.44
SCN10A Q9Y5Y9 1/20 0.44
GSK3B P49841 1/20 0.39
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26664974 1.00 CYP19A1 (0.69) CYP19A1CACNA1FSCN1ASCN4ACACNA1D
SCHEMBL15196027 1.00 CYP19A1 (0.69) CYP19A1CACNA1FSCN1ASCN4ACACNA1D
SCHEMBL2054565 1.00 CYP19A1 (0.69) CYP19A1CACNA1FSCN1ASCN4ACACNA1D
SCHEMBL14520901 0.83 CYP19A1 (0.72) CYP19A1KCNH2MAOBMAOACXCR3
SCHEMBL4556388 0.83 CYP19A1 (0.72) CYP19A1KCNH2MAOBMAOACXCR3
SCHEMBL10530071 0.81 CYP19A1 (1.00) CYP19A1ALDH1A1
SCHEMBL8245665 0.81 CYP19A1 (0.70) CYP19A1MMP2MMP9KDM1ACXCR3
SCHEMBL22623727 0.81 CYP19A1 (1.00) CYP19A1ALDH1A1
SCHEMBL10530941 0.81 CYP19A1 (1.00) CYP19A1ALDH1A1
SCHEMBL13201868 0.81 CYP19A1 (0.70) CYP19A1MMP2MMP9KDM1ACXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119579143-A Intelligent paint production full-flow monitoring and optimizing system, method and medium 广东卓和高新材料有限公司 2025-03-07 CN claimed
CN-116078359-A Multilayer film of graphene oxide-polymer microgel and preparation method and application thereof 中国人民解放军空军军医大学 2023-05-09 CN claimed
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2026-04-21 US disclosed
CN-119579143-A Intelligent paint production full-flow monitoring and optimizing system, method and medium 广东卓和高新材料有限公司 2025-03-07 CN disclosed
CN-119432998-A Kit for detecting phenylketonuria pathogenic gene and application thereof 郑州大学第三附属医院(河南省妇幼保健院) 2025-02-14 CN disclosed
US-20240398959-A1 C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
CN-118103436-A Depolymerization of polyhydroxyalkanoates and recovery of the polyhydroxyalkanoate monomers obtained by metabolic processes 金伯利-克拉克环球有限公司 2024-05-28 CN disclosed
US-11992531-B2 C3-carbon linked glutarimide degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2024-05-28 US disclosed
US-11974977-B2 Composition and uses for influencing hair growth LUCOLAS—M.D. LTD (GB) 2024-05-07 US disclosed
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-4839379-A AROMATASE INHIBITORS CIBA-GEIGY CORPORATION (US) 1989-06-13 US disclosed
EP-0114033-B1 SUBSTITUTED AZABICYCLOALKANES, THEIR USE, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THESE COMPOUNDS CIBA-GEIGY AG (CH) 1988-10-12 EP disclosed
EP-0114033-A1 Substituted azabicycloalkanes, their use, pharmaceutical preparations containing these compounds and process for preparing these compounds CIBA-GEIGY AG (CH) 1984-07-25 EP disclosed
EP-0114033-A1 Substituted azabicycloalkanes, their use, pharmaceutical preparations containing these compounds and process for preparing these compounds CIBA-GEIGY AG (CH) 1984-07-25 EP disclosed
US-4435419-A Method of treating depression using azabicyclohexanes AMERICAN CYANAMID COMPANY (US) 1984-03-06 US disclosed
US-4231935-A ANXIOLYTICS AND ANALGESICS AMERICAN CYANAMID COMPANY (US) 1980-11-04 US disclosed
US-4196120-A 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS AMERICAN CYANAMID COMPANY (US) 1980-04-01 US disclosed
US-4131611-A ANXIOLYTIC, ANALGESIC AMERICAN CYANAMID COMPANY (US) 1978-12-26 US disclosed
US-4088652-A Acylazabicyclohexanes AMERICAN CYANAMID COMPANY (US) 1978-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF CRBN, CRKL, ERBB3 CYP19A1 3947/4885CACNA1F 3739/4885SCN1A 4340/4885
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation NEDD4, UBE3A, UBE3C CYP19A1 2859/4885CACNA1F 4600/4885SCN1A 1316/4885
US-11992531-B2 C3-carbon linked glutarimide degronimers for target protein degradation STUB1, UBE3C, UBE3A CYP19A1 1336/4885CACNA1F 4810/4885SCN1A 4754/4885
US-20240398959-A1 C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A CYP19A1 1336/4885CACNA1F 4810/4885SCN1A 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.